127 related articles for article (PubMed ID: 37659754)
21. AgNOR count as objective marker for dysplastic features in oral leukoplakia.
Chattopadhyay A; Ray JG; Caplan DJ
J Oral Pathol Med; 2002 Oct; 31(9):512-7. PubMed ID: 12269989
[TBL] [Abstract][Full Text] [Related]
22. Estimation of salivary lactate dehydrogenase in oral leukoplakia and oral squamous cell carcinoma: a biochemical study.
Patel S; Metgud R
J Cancer Res Ther; 2015; 11(1):119-23. PubMed ID: 25879348
[TBL] [Abstract][Full Text] [Related]
23. Nomogram for risk prediction of malignant transformation in oral leukoplakia patients using combined biomarkers.
Zhang X; Kim KY; Zheng Z; Bazarsad S; Kim J
Oral Oncol; 2017 Sep; 72():132-139. PubMed ID: 28797449
[TBL] [Abstract][Full Text] [Related]
24. Estimation of salivary lactate dehydrogenase in oral squamous cell carcinoma, oral leukoplakia, and smokers.
Bhuvaneswari M; Prasad H; Rajmohan M; Sri Chinthu KK; Prema P; Mahalakshmi L; Kumar GS
J Cancer Res Ther; 2022 Dec; 18(Supplement):S215-S218. PubMed ID: 36510967
[TBL] [Abstract][Full Text] [Related]
25. Salivary metabolomics with alternative decision tree-based machine learning methods for breast cancer discrimination.
Murata T; Yanagisawa T; Kurihara T; Kaneko M; Ota S; Enomoto A; Tomita M; Sugimoto M; Sunamura M; Hayashida T; Kitagawa Y; Jinno H
Breast Cancer Res Treat; 2019 Oct; 177(3):591-601. PubMed ID: 31286302
[TBL] [Abstract][Full Text] [Related]
26. Identification of Proteomic Biomarkers in Proliferative Verrucous Leukoplakia through Liquid Chromatography With Tandem Mass Spectrometry.
Arroyo E; Pérez Sayáns M; Bravo SB; de Oliveira Barbeiro C; Paravani Palaçon M; Chamorro Petronacci CM; García Vence M; Chantada Vázquez MDP; Blanco Carrión A; Suárez Peñaranda JM; García García A; Gándara Vila P; Días Almeida J; Veríssimo da Costa GC; Sousa Nogueira FC; Medeiros Evaristo JA; de Abreu Pereira D; Rintala M; Salo T; Rautava J; Padín Iruegas E; Oliveira Alves MG; Morandin Ferrisse T; Albergoni da Silveira H; Esquiche León J; Vilela Silva E; Flores IL; Bufalino A
Lab Invest; 2023 Oct; 103(10):100222. PubMed ID: 37507024
[TBL] [Abstract][Full Text] [Related]
27. Oral leukoplakia manifests differently in smokers and non-smokers.
Lima JS; Pinto Ddos S; Sousa SO; Corrêa L
Braz Oral Res; 2012; 26(6):543-9. PubMed ID: 23019086
[TBL] [Abstract][Full Text] [Related]
28. Differential diagnosis of lung cancer and benign lung lesion using salivary metabolites: A preliminary study.
Takamori S; Ishikawa S; Suzuki J; Oizumi H; Uchida T; Ueda S; Edamatsu K; Iino M; Sugimoto M
Thorac Cancer; 2022 Feb; 13(3):460-465. PubMed ID: 34918488
[TBL] [Abstract][Full Text] [Related]
29. Salivary microRNAs in oral cancer.
Zahran F; Ghalwash D; Shaker O; Al-Johani K; Scully C
Oral Dis; 2015 Sep; 21(6):739-47. PubMed ID: 25784212
[TBL] [Abstract][Full Text] [Related]
30. Identification of salivary metabolic biomarker signatures for oral tongue squamous cell carcinoma.
Vimal J; George NA; Kumar RR; Kattoor J; Kannan S
Arch Oral Biol; 2023 Nov; 155():105780. PubMed ID: 37586141
[TBL] [Abstract][Full Text] [Related]
31. Chewing tobacco may act as a risk factor for dysplastic transformation of squamous cells in Oral leukoplakia- A cytochemistry based approach.
Bhattacharyya S; Ray S; Saha D; Mustafi SM; Alam N; Sarkar A; Murmu N
Pathol Res Pract; 2021 Feb; 218():153287. PubMed ID: 33454586
[TBL] [Abstract][Full Text] [Related]
32. Increased ΔNp63 expression is predictive of malignant transformation in oral epithelial dysplasia and poor prognosis in oral squamous cell carcinoma.
Matsubara R; Kawano S; Kiyosue T; Goto Y; Hirano M; Jinno T; Toyoshima T; Kitamura R; Oobu K; Nakamura S
Int J Oncol; 2011 Dec; 39(6):1391-9. PubMed ID: 21833468
[TBL] [Abstract][Full Text] [Related]
33. Binding pattern of eight different lectins in healthy subjects and patients with dysplastic and malignant lesions of the oral cavity.
Mazumdar S; SenGupta SK; Param R; Sinha SN
Int J Oral Maxillofac Surg; 1993 Oct; 22(5):301-5. PubMed ID: 8245572
[TBL] [Abstract][Full Text] [Related]
34. Development and validation of nomogram for prediction of malignant transformation in oral leukoplakia: A large-scale cohort study.
Wang T; Wang L; Yang H; Lu H; Zhang J; Li N; Guo CB
J Oral Pathol Med; 2019 Jul; 48(6):491-498. PubMed ID: 30980769
[TBL] [Abstract][Full Text] [Related]
35. Podoplanin expression as a predictive marker of dysplasia in oral leukoplakia.
Gissi DB; Gabusi A; Tarsitano A; Luccarini L; Morandi L; Montebugnoli L
J Craniomaxillofac Surg; 2018 May; 46(5):759-764. PubMed ID: 29588189
[TBL] [Abstract][Full Text] [Related]
36. High density of CD8 T cell and immune imbalance of T lymphocytes subsets are associated with proliferative verrucous leukoplakia.
Fernandes D; Barbeiro CO; Palaçon MP; Biancardi MR; Ferrisse TM; Silveira HA; Castilho RM; de Almeida LY; Leon JE; Bufalino A
Immunology; 2023 Jan; 168(1):96-109. PubMed ID: 36056642
[TBL] [Abstract][Full Text] [Related]
37. Oral leukoplakia: A clinicopathological study and malignant transformation.
Tovaru S; Costache M; Perlea P; Caramida M; Totan C; Warnakulasuriya S; Parlatescu I
Oral Dis; 2023 May; 29(4):1454-1463. PubMed ID: 34982498
[TBL] [Abstract][Full Text] [Related]
38. E-cadherin as a potential biomarker of malignant transformation in oral leukoplakia: a retrospective cohort study.
von Zeidler SV; de Souza Botelho T; Mendonça EF; Batista AC
BMC Cancer; 2014 Dec; 14():972. PubMed ID: 25518919
[TBL] [Abstract][Full Text] [Related]
39. Semiquantifiable angiogenesis parameters in association with the malignant transformation of oral leukoplakia.
Thiem DGE; Schneider S; Venkatraman NT; Kumar VV; Brieger J; Frerich B; Kämmerer PW
J Oral Pathol Med; 2017 Oct; 46(9):710-716. PubMed ID: 28036153
[TBL] [Abstract][Full Text] [Related]
40. Annual malignant transformation rate of oral leukoplakia remains consistent: A long-term follow-up study.
Evren I; Brouns ER; Wils LJ; Poell JB; Peeters CFW; Brakenhoff RH; Bloemena E; de Visscher JGAM
Oral Oncol; 2020 Nov; 110():105014. PubMed ID: 33038723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
